UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR
15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): July 6, 2020
CHROMADEX CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware
|
001-37752
|
26-2940963
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
10900 Wilshire Blvd. Suite 600, Los Angeles, California
90024
(Address
of principal executive offices, including zip code)
(310) 388-6706
(Registrant's telephone number, including area
code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
] Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
[
] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
CDXC
|
The
Nasdaq Capital Market
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
ChromaDex
Corporation (the “Company” or “ChromaDex”)
recently became aware that, due to an administrative error, certain
of the Company’s previously filed Annual Reports on Form
10-K, including the Annual Report on Form 10-K for the year ended
December 31, 2019, as amended, contained the wrong filing, issued
and/or expiration dates with respect to certain of the
Company’s owned and licensed patents. The following table
sets forth the Company’s existing owned and licensed patents
with such filing, issued and/or expiration dates as
corrected:
Patent Number
|
Title
|
Filing Date
|
Issued Date
|
Expires
|
Licensor
|
7,205,284
|
Potent
immunostimulants from microalgae
|
7/10/2001
|
4/17/2007
|
3/9/2022
|
Licensed
from University of Mississippi
|
7,776,326
|
Methods
and compositions for treating neuropathies
|
6/3/2005
|
8/17/2010
|
6/24/2026
|
Licensed
from Washington University
|
7,846,452
|
Potent
immunostimulatory extracts from microalgae
|
7/28/2005
|
12/7/2010
|
7/28/2025
|
Licensed
from University of Mississippi
|
8,106,184
|
Nicotinyl
Riboside Compositions and Methods of Use
|
11/17/2006
|
1/31/2012
|
9/20/2027
|
Licensed
from Cornell University
|
8,114,626
|
Yeast
strain and method for using the same to produce Nicotinamide
Riboside
|
3/26/2009
|
2/14/2012
|
1/5/2026
|
Licensed
from Dartmouth College
|
8,133,917
|
Pterostilbene
as an agonist for the peroxisome proliferator-activated receptor
alpha isoform
|
10/25/2010
|
3/13/2012
|
8/18/2025
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
8,197,807
|
Nicotinamide
Riboside Kinase compositions and Methods for using the
same
|
4/20/2006
|
6/12/2012
|
11/19/2026
|
Licensed
from Dartmouth College
|
8,252,845
|
Pterostilbene
as an agonist for the peroxisome proliferator-activated receptor
alpha isoform
|
2/1/2012
|
8/28/2012
|
8/18/2025
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
8,318,807
|
Pterostilbene
Caffeine Co-Crystal Forms
|
7/30/2010
|
11/27/2012
|
7/21/2031
|
Licensed
from Laurus Labs Private Limited
|
8,383,086
|
Nicotinamide
Riboside Kinase compositions and Methods for using the
same
|
4/12/2012
|
2/26/2013
|
4/20/2026
|
Licensed
from Dartmouth College
|
8,399,712
|
Pterostilbene
cocrystals
|
7/30/2010
|
3/19/2013
|
8/10/2031
|
Licensed
from Laurus Labs Private Limited
|
8,524,782
|
Key
intermediate for the preparation of Stilbenes, solid forms of
Pterostilbene, and methods for making the same
|
1/21/2011
|
9/3/2013
|
2/1/2030
|
Licensed
from Laurus Labs Private Limited
|
8,809,400
|
Method
to Ameliorate Oxidative Stress and Improve Working Memory Via
Pterostilbene Administration
|
8/8/2011
|
8/19/2014
|
10/2/2028
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
8,841,350
|
Method
for treating non-melanoma skin cancer by inducing
UDP-Glucuronosyltransferase activity using
pterostilbene
|
5/8/2012
|
9/23/2014
|
5/8/2032
|
Co-owned
by ChromaDex and University of California
|
8,889,126
|
Methods
and compositions for treating neuropathies
|
5/28/2010
|
11/18/2014
|
6/3/2025
|
Licensed
from Washington University
|
9,000,147
|
Nicotyl
riboside compositions and methods of use
|
1/17/2012
|
4/7/2015
|
11/17/2026
|
Licensed
from Cornell University
|
9,028,887
|
Method
improve spatial memory via pterostilbene
administration
|
5/22/2014
|
5/12/2015
|
6/10/2028
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
9,295,688
|
Methods
and compositions for treating neuropathies
|
10/10/2014
|
3/29/2016
|
6/3/2025
|
Licensed
from Washington University
|
9,321,797
|
Nicotyl
riboside compositions and methods of use
|
11/17/2014
|
4/26/2016
|
11/17/2026
|
Licensed
from Cornell University
|
9,439,875
|
Anxiolytic
effect of pterostilbene
|
5/11/2011
|
9/13/2016
|
12/11/2031
|
Licensed
from the University of Mississippi and U.S. Department of
Agriculture
|
9,975,915
|
Crystalline
forms of nicotinoyl ribosides, modified derivatives thereof, and
phosphorylated analogs thereof, and methods of preparation
thereof
|
11/10/2017
|
5/22/2018
|
11/10/2037
|
Co-owned
by ChromaDex and The Queen’s University of
Belfast
|
10,000,519
|
Methods of Preparing Nicotinamide Riboside and Derivatives
Thereof
|
7/24/2014
|
6/19/2018
|
7/24/2034
|
Licensed from The Queen’s University of
Belfast
|
10,000,520
|
B-vitamin
and amino acid conjugates ofnicotinoyl ribosides and reduced
nicotinoyl ribosides, derivatives thereof, and methods of
preparation thereof
|
3/16/2017
|
6/19/2018
|
3/16/2037
|
Co-owned
by ChromaDex and The Queen’s University of
Belfast
|
10,183,036
|
Use of nicotinic acid riboside or nicotinamide riboside
derivatives, and reduced derivatives thereof, as NAD+ increasing
precursors
|
4/20/2017
|
1/22/2019
|
4/20/2037
|
Owned by ChromaDex
|
10,280,190
|
Nicotinic acid riboside or nicotinamide riboside compositions,
reduced derivatives thereof, and the use thereof to enhance skin
permeation in treating skin conditions
|
3/16/2016
|
5/7/2019
|
5/31/2036
|
Co-owned by ChromaDex and The Queen’s University of
Belfast
|
10,688,118
|
Nicotinamide riboside compositions for topical use in treating skin
conditions
|
10/30/2014
|
6/23/2020
|
4/6/2035
|
Owned by ChromaDex
|
10,689,411
|
Efficient and scalable syntheses of nicotinoyl ribosides and
reduced nicotinoyl ribosides, modified derivatives thereof,
phosphorylated analogs thereof, adenylyl dinucleotide conjugates
thereof, and novel crystalline forms
thereof
|
11/10/2017
|
6/23/2020
|
11/10/2037
|
Co-owned by ChromaDex and The Queen’s University of
Belfast
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CHROMADEX CORPORATION
|
||
|
|
|
||||
Dated:
July 8, 2020
|
|
|
|
|
||
|
|
|
|
|||
|
|
|
|
By:
|
|
/s/
Kevin M.
Farr
|
|
|
|
|
|
|
Name:
Kevin M. Farr
|
|
|
|
|
|
|
Chief
Financial Officer
|